Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
Huang, Ying, Zhang, Jeff, Sendzik, Martin, Gao, Zhenting, Sun, Yongfeng, Wang, Long, Zhang, Lijun, Blanz, Joachim, Dubost, Valerie, Chen, Zijun, Fang, Douglas, Gu, Justin, Kiffe, Michael, Li, Ling, Luo, Fangjun, Luo, Xiao, Mistry, Prakash, Pearson, David, Piaia, Alessandro, Qi, Wei, Scheufler, Clemens, Terranova, Remi, Weiss, Andreas, Yu, Zhengtian, Zeng, Jue, Zhang, Hailong, Zhang, Jiangwei, Zhang, Qiong, Zhao, Kehao, Zhao, Mengxi, Atadja, Peter, Dillon, Michael, Jeay, Sebastien Jeay, Li, En, Moggs, Jonathan, Pissot Soldermann, Carole, Oyang, Counde and Lingel, Andreas (2022) Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. Journal of Medicinal Chemistry, 65 (7). pp. 5317-5333. ISSN 0022-26231520-4804
Abstract
Polycomb Repressive Complex 2 (PRC2) plays an important role in transcriptional regulation during animal development and in cell differentiation, and alteration of PRC2 activity has been associated with cancer. On a molecular level, PRC2 catalyzes methylation of histone H3 lysine 27 (H3K27), resulting in mono-, di-, or trimethylated forms of H3K27, of which the trimethylated form H3K27me3 leads to transcriptional repression of polycomb target genes. Previously, we have shown that binding of the low-molecular-weight compound EED226 to the H3K27me3 binding pocket of the regulatory subunit EED can effectively inhibit PRC2 activity in cells and reduce tumor growth in mouse xenograft models. Here, we report the stepwise optimization of the tool compound EED226 toward the potent and selective EED inhibitor MAK683 (compound 22) and its subsequent preclinical characterization. Based on a balanced PK/PD profile, efficacy, and mitigated risk of forming reactive metabolites, MAK683 has been selected for clinical development.
Item Type: | Article |
---|---|
Keywords: | Animals Enzyme Inhibitors Histones Humans Methylation Mice Neoplasms Polycomb Repressive Complex 2 |
Date Deposited: | 14 Jun 2022 00:45 |
Last Modified: | 14 Jun 2022 00:45 |
URI: | https://oak.novartis.com/id/eprint/46016 |